

FDA EXTENDS REVIEW OF ARZERRA™ (OFATUMUMAB)

Summary: GlaxoSmithKline and Genmab announced that the FDA extends review ARZERRA by three months.

London, UK and Copenhagen, Denmark; June 16, 2009 – GlaxoSmithKline (NYSE: GSK) and Genmab A/S (OMX: GEN) today announced that the United States Food and Drug Administration (FDA) informed the companies that the agency has extended the action date for the ofatumumab BLA application by three months.

The BLA was submitted on January 30, 2009 and was granted priority review by the FDA. Under priority review, the FDA sets the target date for a decision at six months, rather than the standard 10 month review. The three month extension will allow the agency to review additional chemistry and manufacturing data submitted on June 5. The new action date for the BLA is October 31, 2009.

An FDA Oncology Drugs Advisory Committee (ODAC), held on May 29, 2009, voted 10-3 that ofatumumab was likely to offer clinical benefit for certain patients with chronic lymphocytic leukemia (CLL). Data from the pivotal trial of ofatumumab were presented at the American Society of Hematology 2008 annual meeting and at American Society of Clinical Oncology 2009 annual meeting.

CLL is the most common adult leukemia and one of the most common malignant lymphoid diseases. In the United States, about 90,000 people are living with CLL, with approximately 15,000 estimated new cases being diagnosed in 2009.

GSK and Genmab are committed to working with the FDA in order to bring this potential new treatment option to patients.

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information, visit GlaxoSmithKline at www.gsk.com.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients

FDA EXTENDS REVIEW OF ARZERRA™ (OFATUMUMAB)

who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

GlaxoSmithKline Enquiries:

UK Media enquiries	Philip Thomson David Outhwaite Stephen Rea	(020) 8047 5502 (020) 8047 5502 (020) 8047 5502
US Media enquiries	Lisa Behrens Ken Inchausti	(919) 699 1758 (919) 699 1758
European Analyst/ Investor enquiries	David Mawdsley Sally Ferguson Gary Davies	(020) 8047 5564 (020) 8047 5543 (020) 8047 5503
US Analyst/ Investor enquiries	Tom Curry Jen Hill Baxter	(215) 751 5419 (215) 751 7002

Genmab Enquiries

Vice President, Investor Relations	Helle Husted	T +45 33 44 77 30 M +45 25 27 47 13 hth@genmab.com
------------------------------------	--------------	--

Cautionary statement regarding forward-looking statements for GSK:

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007.

Registered in England and Wales

No. 3888792

Registered Office:

980 Great West Road
Brentford, Middlesex
TW8 9GS

Forward Looking Statement for Genmab:

This Stock Exchange Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S
Bredgade 34
1260 Copenhagen K, Denmark
Tel: +45 7020 2728
Fax: +45 7020 2729
CVR no. 2102 3884

Stock Exchange Release no. 22/2009
Page 2/3

FDA EXTENDS REVIEW OF ARZERRA™ (OFATUMUMAB)

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax-EGFr™; HuMax-IL8™; HuMax-TAC™; HuMax-HepC™; HuMax-CD38™; HuMax-CD32b™; HuMax-TF™; HuMax-Her2™; HuMax-VEGF™ and UniBody® are all trademarks of Genmab A/S. Arzerra™ is a trademark of GlaxoSmithKline.

###